Dear Editor,
A recent study published in Nature by Douaud and colleagues1 shows that SARS-CoV-2 infection is associated with longitudinal effects, particularly on brain structures linked to the olfactory cortex, modestly accelerated reduction in global brain volume, and enhanced cognitive decline. Thus, even mild COVID-19 can be associated with long-lasting deleterious effects on brain structure and function.
Loss of smell and taste are amongst the earliest and most common effects of SARS-CoV-2 infection. In addition, headaches, memory problems, confusion, or loss of speech and motility occur in some individuals.2 While important progress has been made in understanding SARS-CoV-2-associated neurological manifestations, the underlying mechanisms are under debate and most knowledge stems from analyses of hospitalized patients with severe COVID-19.2 Most infected individuals, however, develop mild to moderate disease and recover without hospitalization. Whether or not mild COVID-19 is associated with long-term neurological manifestations and structural changes indicative of brain damage remained largely unknown.
Douaud and co-workers examined 785 participants of the UK Biobank (www.ukbiobank.ac.uk) who underwent magnetic resonance imaging (MRI) twice with an average inter-scan interval of 3.2 years, and 401 individuals testing positive for SARS-CoV-2 infection between MRI acquisitions (Fig. 1a). Strengths of the study are the large number of samples, the availability of scans obtained before and after infection, and the multi-parametric quantitative analyses of serial MRI acquisitions.1 These comprehensive and automated analyses with a non-infected control group allowed the authors to dissect consistent brain changes caused by SARS-CoV-2 infection from pre-existing conditions. Altogether, the MRI scan processing pipeline used extracted more than 2,000 features, named imaging-derived phenotypes (IDPs), from each participant’s imaging data. Initially, the authors focused on IDPs involved in the olfactory system. In agreement with the frequent impairment of smell and taste in COVID-19, they found greater atrophy and indicators of increased tissue damage in the anterior cingulate cortex, orbitofrontal cortex and insula, as well as in the ventral striatum, amygdala, hippocampus and para-hippocampal gyrus, which are connected to the primary olfactory cortex (Fig. 1b). Taking advantage of computational models allowing to differentiate changes related to SARS-CoV-2 infection from physiological age-related brain changes (e.g. decreases of brain volume with aging),3 they also explored IDPs covering the entire brain. Although most individuals experienced only mild symptoms of COVID-19, the authors detected an accelerated reduction in whole-brain volume and more pronounced cognitive declines associated with increased atrophy of a cognitive lobule of the cerebellum (crus II) in individuals with SARS-CoV-2 infection compared to the control group. These differences remained significant when 15 people who required hospitalization were excluded. Most brain changes for IDPs were moderate (average differences between the two groups of 0.2–2.0%, largest for volume of parahippocampal gyrus and entorhinal cortex) and accelerated brain volume loss was “only” observed in 56–62% of infected participants. Nonetheless, these results strongly suggest that even clinically mild COVID-19 might induce long-term structural alterations of the brain and cognitive impairment.
The study provides unique insights into COVID-19-associated changes in brain structure. The authors took great care in appropriately matching the case and control groups, making it unlikely that observed differences are due to confounding factors, although this possibility can never be entirely excluded. The mechanisms underlying these infection-associated changes, however, remain to be clarified. Viral neurotropism and direct infection of cells of the olfactory system, neuroinflammation and lack of sensory input have been suggested as reasons for the degenerative events in olfactory-related brain structures and neurological complications.4 These mechanisms are not mutually exclusive and may synergize in causing neurodegenerative disorders as consequence of COVID-19.
The study participants became infected between March 2020 and April 2021, before the emergence of the Omicron variant of concern (VOC) that currently dominates the COVID-19 pandemic. During that time period, the Alpha and Beta VOCs dominated in the UK and all results were obtained from individuals between 51 and 81 years of age. It will be of great interest to clarify whether Omicron, that seems to be less pathogenic than other SARS-CoV-2 variants, also causes long-term brain damage. The vaccination status of the participants was not available in the study1 and it will be important to clarify whether long-term changes in brain structure also occur in vaccinated and/or younger individuals. Other important questions are whether these structural changes are reversible or permanent and may even enhance the frequency for neurodegenerative diseases that are usually age-related, such as Alzheimer’s, Parkinson’s or Huntington’s disease. Previous findings suggest that cognitive disorders improve over time after severe COVID-19;5 yet it remains to be determined whether the described brain changes will translate into symptoms later in life such as dementia. Douaud and colleagues report that none of top 10 IDPs correlated significantly with the time interval between SARS-CoV-2 infection and the 2nd MRI acquisition, suggesting that the observed abnormalities might be very long-lasting.
Currently, many restrictions and protective measures are relaxed because Omicron is highly transmissible but usually causes mild to moderate acute disease. This raises hope that SARS-CoV-2 may evolve towards reduced pathogenicity and become similar to circulating coronaviruses causing mild respiratory infections. More work needs to be done to clarify whether the current Omicron and future variants of SARS-CoV-2 may also cause lasting brain abnormalities and whether these can be prevented by vaccination or therapy. However, the finding by Douaud and colleagues1 that SARS-CoV-2 causes structural changes in the brain that may be permanent and could relate to neurological decline is of concern and illustrates that the pathogenesis of this virus is markedly different from that of circulating human coronaviruses. Further studies, to elucidate the mechanisms underlying COVID-19-associated neurological abnormalities and how to prevent or reverse them are urgently needed.
References
Douaud, G. et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature 604, 697–707 (2022).
COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet 398, 1700–1712 (2021).
Alfaro-Almagro, F. et al. Confound modelling in UK Biobank brain imaging. Neuroimage 224, 117002 (2021).
Galea, M., Agius, M. & Vassallo, N. Neurological manifestations and pathogenic mechanisms of COVID-19. Neurol. Res. 1–12 (2022) https://doi.org/10.1080/01616412.2021.2024732.
Ferrucci, R. et al. One-year cognitive follow-up of COVID-19 hospitalized patients. Eur. J. Neurol. (2022) https://doi.org/10.1111/ene.15324.
Funding
The authors are supported by the DFG (CRCs 1279 and 1506) as well as the BMBF (Restrict-SARS-CoV-2). Open Access funding enabled and organized by Projekt DEAL.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Sollmann, N., Beer, A.J. & Kirchhoff, F. SARS-CoV-2 infection and the brain: direct evidence for brain changes in milder cases. Sig Transduct Target Ther 7, 230 (2022). https://doi.org/10.1038/s41392-022-01072-1
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41392-022-01072-1
This article is cited by
-
Dementia, infections and vaccines: 30 years of controversy
Aging Clinical and Experimental Research (2023)
-
Overview of the potential use of fluvoxamine for COVID-19 and long COVID
Discover Mental Health (2023)